Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mag-epa oil + orlistat
- Development stage
- Preclinical
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MAG-EPA oil + orlistat is a combination drug consisting of **MAG-EPA oil** (monoacylglycerol form of eicosapentaenoic acid, an omega-3 fatty acid) and **orlistat** (a gastrointestinal lipase inhibitor)[5][2]. Orlistat acts by inhibiting gastric and pancreatic lipases, thereby preventing the hydrolysis and absorption of dietary triglycerides; this leads to reduced fat absorption and promotes weight loss[6][7][1]. MAG-EPA oil provides EPA, a long-chain polyunsaturated fatty acid important for cardiovascular and metabolic health. However, orlistat reduces the absorption of EPA and other long-chain n-3 polyunsaturated fatty acids when administered together[2]. This combination is used in clinical trials to evaluate their synergistic effects on lipid metabolism, obesity, and metabolic diseases. Combining orlistat with fish oil (MAG-EPA) may affect the pharmacokinetics and bioavailability of EPA, with orlistat reducing overall fat absorption, including beneficial fatty acids[2][5]. Primary investigational indications are obesity and related metabolic disorders.
- Other names
- mag-epa oil + orlistat
02
Targets
LIPF (Gastric lipase)PNLIP (Pancreatic triacylglycerol lipase)
Beyond the preview
Go deeper on mag-epa oil + orlistat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mag-epa oil + orlistat.